Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Surg Obes Relat Dis. 2017 Aug;13(8):1337-1346. doi: 10.1016/j.soard.2017.04.003. Epub 2017 Apr 7.
Limited evidence suggests bariatric surgery may not reduce opioid analgesic use, despite improvements in pain.
To determine if use of prescribed opioid analgesics changes in the short and long term after bariatric surgery and to identify factors associated with continued and postsurgery initiated use.
Ten U.S. hospitals.
The Longitudinal Assessment of Bariatric Surgery-2 is an observational cohort study. Assessments were conducted presurgery, 6 months postsurgery, and annually postsurgery for up to 7 years until January 2015. Opioid use was defined as self-reported daily, weekly, or "as needed" use of a prescribed medication classified as an opioid analgesic.
Of 2258 participants with baseline data, 2218 completed follow-up assessment(s) (78.7% were female, median body mass index: 46; 70.6% underwent Roux-en-Y gastric bypass). Prevalence of opioid use decreased after surgery from 14.7% (95% CI: 13.3-16.2) at baseline to 12.9% (95% CI: 11.5-14.4) at month 6 but then increased to 20.3%, above baseline levels, as time progressed (95% CI: 18.2-22.5) at year 7. Among participants without baseline opioid use (n = 1892), opioid use prevalence increased from 5.8% (95% CI: 4.7-6.9) at month 6 to 14.2% (95% CI: 12.2-16.3) at year 7. Public versus private health insurance, more pain presurgery, undergoing subsequent surgeries, worsening or less improvement in pain, and starting or continuing nonopioid analgesics postsurgery were significantly associated with higher risk of postsurgery initiated opioid use.
After bariatric surgery, prevalence of prescribed opioid analgesic use initially decreased but then increased to surpass baseline prevalence, suggesting the need for alternative methods of pain management in this population.
有限的证据表明,减重手术后疼痛改善,但阿片类镇痛药的使用可能并未减少。
确定减重手术后短期和长期内是否会改变规定阿片类镇痛药的使用,并确定与持续使用和术后开始使用相关的因素。
美国 10 家医院。
《肥胖手术的纵向评估-2》是一项观察性队列研究。评估在术前、术后 6 个月和术后每年进行,最长可达 7 年,直至 2015 年 1 月。阿片类药物的使用定义为自我报告的每日、每周或“按需”使用被归类为阿片类镇痛药的规定药物。
在 2258 名有基线数据的参与者中,2218 名完成了随访评估(78.7%为女性,中位数体重指数:46;70.6%接受 Roux-en-Y 胃旁路术)。手术后,阿片类药物的使用比例从基线时的 14.7%(95%CI:13.3-16.2)下降到术后 6 个月的 12.9%(95%CI:11.5-14.4),但随着时间的推移,到第 7 年时增加到 20.3%,高于基线水平(95%CI:18.2-22.5)。在没有基线阿片类药物使用的参与者中(n=1892),阿片类药物的使用比例从术后 6 个月的 5.8%(95%CI:4.7-6.9)增加到第 7 年的 14.2%(95%CI:12.2-16.3)。公共医疗保险与私人医疗保险、术前更多疼痛、随后的手术、疼痛恶化或改善较少、术后开始或继续使用非阿片类镇痛药与术后开始使用阿片类药物的风险增加显著相关。
减重手术后,规定阿片类镇痛药的使用比例最初下降,但随后增加到超过基线水平,表明该人群需要采用替代方法来管理疼痛。